loxo strateg even robust
premium near-term dilut
strateg potenti multipl first-in-class launch
think loxo transact announc morn make good strateg
sens expand lilli oncolog portfolio target therapi
potenti multipl first-in-class product launch could drive
revenu growth margin expans deal would largest
lilli histori add us-approv product trk inhibitor vitrakvi
ou partnership bayer well pipelin asset notabl
potenti best/first-in-class ret inhibitor breakthrough
therapi design could file fda later year
potenti dilut lilli updat guidanc
call feb still work final account deal
deal dilut bottom line estim ep
dilut lilli current non-gaap ep guidanc
use current consensu estim loxo assum
synergi debt financ interest rate base
consensu forecast loxo deal look slightli accret
lilli state expect deal potenti accret cash
basi
set posit environ biopharma
larg cap compani rel quiet busi develop front
especi relat larger deal despit passag us
corpor tax reform end allow easier access ex-
us cash howev silenc shatter far
mega-merg bristol celgen loxo deal
two deal could signal robust environ
think bolt-on deal still like mega-merg would
benefit smid-cap biopharma compani includ coverag
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
trulic jardianc taltz galcanezumab olumi verzenio
lartruvo compar current base case assumpt also
model higher gross margin oper margin base
case assumpt blue sky valuat base dcf driven
wacc termin valu assign lilli
share elanco per share
grey sky valuat base lower sale trulic
jardianc taltz galcanezumab olumi verzenio lartruvo
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
assign lilli share elanco per share
 close
asset acquir deal
think deal expens believ make strateg sens lilli
expand compani oncolog portfolio addit target therapi asset
provid opportun potenti launch multipl first-in-class best-in-class
therapi near- to-mid-term could drive revenu growth margin expans
compani believ key loxo asset pipelin target therapi
specif mutat across multipl tumor type potenti robust single-ag
activ limit off-target side effect lilli expect loxo deal close end
deal lilli add one alreadi fda approv product first-in-class trk inhibitor
vitrakvi well three addit clinical-stag pipelin product lilli see
acceler approv vitrakvi agnost tumor type valid loxo
target therapi approach loxo ex-u partnership bayer vitrakvi lilli
want dissolv partnership post-deal
import pipelin asset potenti first-in-class ret inhibitor
current phase current plan regulatori
discuss phase data expect potenti us file late
could lead approv breakthrough design
ret-fus posit nsclc make nsclc
ret-mut medullari thyroid cancer account medullari thyroid
way background genom alter ret kinas includ fusion
activ point mutat lead overact ret signal uncontrol cell growth
ret fusion identifi approxim non-smal cell lung cancer
papillari thyroid cancer subset cancer activ ret
point mutat account approxim medullari thyroid cancer mtc
ret fusion cancer ret-mut mtc primarili depend singl activ
kinas prolifer surviv depend often refer oncogen
addict render tumor highli suscept small molecul inhibitor target
lilli expect updat potenti financi impact call februari
compani still work final account transact still
determin whether treat deal asset acquisit busi combin
key differ two account treatment boil
asset acquisit in-process signific portion
acquisit cost would go in-process expens immedi
busi combin much valu capit assess
period basi impair
base commentari compani initi analysi estim
loxo deal could dilut lilli current non-gaap ep guidanc
calcul assum cash use lilli note
guidanc alreadi contempl cash acquisit impli lilli
could see addit financ debt assum new debt
interest rate
biggest impact line spend continu progress
portfolio manag expect addit spend rang
progress pipelin calcul make use consensu forecast loxo
see modest accret deal appear back manag
expect potenti accret cash basi
offer valu loxo equiti
fund equiti
fund
new debt combin compani book
new interest expens deal
rev
rev
larger cap compani still hunt deal
larg cap compani rel quiet busi develop front
especi relat larger deal despit passag us corpor tax
reform end allow easier access ex-u cash
street thought could lead us-domicil compani becom acquisit
howev mega-d bristol celgen follow deal
lilli loxo look like quiet deal front disrupt see
capac deal big small would like benefit
smid-cap biotech name manag commentari
earn continu place emphasi busi develop seem
manag prefer small deal larg transform deal often quit
believ remain critic import larg cap compani area
close watch investor given increas competit certain
therapeut area oncolog inflamm neurosci need play catch-
diversif greater need product blockbust potenti
increas speed innov immuno-oncolog gene therapi chang price
reimburs environ
figur busi develop prioriti larg cap compani
area focu
cs view
continu use strong balanc sheet augment pipelin primari focu
opportun drive growth time frame area interest
includ immunolog oncolog neurosci
larger deal seem less like current pipelin come
focu humira biosimilar impact eu better understood
busi develop remain key pillar compani strategi look
asset strateg align prioriti scientif potenti
immuno-oncolog boost near-to-mid term pipelin remain clear
area focu given recent celg deal
prioriti fund core oper busi develop core
therapeut area find valu interest growth cost synergi
focus somewhat earlier stage asset see better price
point opportun ambit step game
tend focu smaller deal loxo acquisit would
largest compani histori
primari focu alloc capit invest busi
dividend follow right price right time creat
valu sharehold final share repurchas alway avail us
capit alloc effici way import
invest platform believ signific growth
complet actelion acquisit would surpris
see larger pharma deal near futur strong balanc sheet
leav mani option tabl valu creativ deal recent
singl asset earlier stage develop time
 imbruvica darzalex xarelto could area focu
meaning acquisit
continu focus innov consolid strategi
look opportun rule anyth look
across whole spectrum opportun agnost size tri find
opportun acquir scienc lead us great drug
differenti make meaning impact unmet medic need
continu return cash sharehold share repurchas dividend
would strongli favor busi develop boost mid-lat
stage pipelin add addit growth driver stori
beyond keytruda/oncolog gardasil
look capit alloc plan scan
market opportun bring oper destruct
larg could bring could enhanc growth trajectori pipelin
decreas investor focu larger deal mid-siz deal still
possibl bring multipl growth driver innov busi
believ mani smid-cap compani like seen potenti takeout
busi develop candid particularli light increasingli attract
valuat past month smid name experienc signific stock price
pressur especi back half
given partnership gilead filgotinib galapago could attract candid
eye new gilead ceo larg cap compani look galapago
pipelin asset emerg cgrp therapi treat migrain
investor could see alder good takeout candid well although
fourth entrant market given bristol gener deal nektar agent
view favor potenti takeout also
molecul in-hous one name watch may portola given wholly-own
factor xa revers agent andexxa stock lost much valu given
disappoint bevyxxa launch
figur number potenti takeout candid smid cap coverag
main area focu
statu lead asset
inflamm immunolog
phase partner
bla submit
us million unless otherwis state
sale
total incom expens
provis incom tax
compani mention price
